Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

NCT06086340 COMPLETED Results posted

A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States

Details

Lead sponsor	Pfizer
Status	COMPLETED
Enrolment	779
Start date	Fri Sep 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer

Interventions

• Palbociclib
• Aromatase Inhibitor

Countries

United States